Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Paukenschlag in USA: Cannabis-Neuregulierung durch DEA sorgt für Kursexplosion!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
26 Leser
Artikel bewerten:
(0)

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015

DUBLIN, Nov. 10, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/jh757f/global_licensing) has announced the addition of the "Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015" report to their offering.

The Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 includes:

  • Trends in licensing dealmaking in the biopharma industry since 2011
  • Analysis of licensing deal structure
  • Case studies of real-life licensing deals
  • Comprehensive listing of licensing deals since 2011
  • Access to licensing contract documents
  • Key financial bnchmarks for headline, upfront, milestone and royalty rates
  • The leading licensing deals by value since 2011
  • Most active licensing dealmakers since 2011
  • The leading licensing partnering resources

In Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

For more information visit

http://www.researchandmarkets.com/research/jh757f/global_licensing

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.